Low-abundance drug resistance mutations: Extending the HIV paradigm to hepatitis B virus

Journal of Infectious Diseases

Volumn 200, Issue 11, 2009, Pages 1798-1799

  Menzo, Stefano ^a   Vincenti, Donatella ^a   Solmone, Mariacarmela ^a   Prosperi, Mattia ^a   Bruselles, Alessandro ^a   Abbate, Isabella ^a   Rozera, Gabriella ^a   Capobianchi, Maria Rosaria ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIBIOTIC RESISTANCE; DRUG TREATMENT FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HIV; HIV INFECTIONS; HUMANS; MUTATION;

EID: 72849122618     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/647991     Document Type: Letter

References (9)

1. Margeridon-Thermet S, Shulman NS, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 2009; 199:1275-1285
2. Lindstrom A, Odeberg J, Albert J. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 2004; 42: 4788-4795. (Pubitemid 39362404) (Pubitemid 39362404)
3. Kim HS, Han KH, Ahn SH, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005; 10: 441-449
4. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR.Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 2009; 83:1718-1726
5. Margeridon-Thermet S, Shulman N, Liu T, et al. Study of HBV quasispecies in nucleotide analog treated and untreated patients using ultra-deep pyrosequencing technology [poster 42]. In: Program and abstracts of the European Association for the Study of the Liver Conference Hepatitis B and C Virus Resistance to Antiviral Therapies (Paris, France). 2008.
6. Simen BB, Simons JF, Huppler Hullsiek K,et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment- naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199:693-701.
7. Johnson JA, Li J-F, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:1112-1122
8. Paredes R, Lalama C, Ribaudo H, et al. Presence of minor populations of Y181C mutants detected by allele-specific PCR and risk of efavirenz failure in treatment-naïve patients: results of an ACTG 5095 case-cohort study [abstract 83]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). 2008:102.
9. Eriksson N, Pachter L, Mitsuya Y, et al. Viral population estimation using pyrosequencing. PLoS Comput Biol 2008; 4:e1000074. (Pubitemid 351811557) (Pubitemid 351811557)